Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738–748.
Nachman PH, Jennette JC, Falk RJ. Chapter31 Primary Glomerular Disease, Immunoglobulin A nephropathy.
In: Brenner and Rector’s The Kidney. 9th ed. Philadelphia: Elsevier; 2012. p. 1141–1150.
D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors.
Am J Kidney Dis. 2000;36(2):227–237.
Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in
Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29(4):526–532.
Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686.
Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA
nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–163.
Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse
therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis.
2001;38(4):736–743.
Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, et al. Corticosteroid therapy in IgA nephropathy.
J Am Soc Nephrol. 2012;23(6):1108–1116.
Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current
treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013;17(6):827–833.
Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, et al. Vertebral fracture and bone mineral
density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol.
2005;32(5):863–869.
Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from
bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol. 2008;35(11):2249–
2254.
Hayashi K, Yamamoto M, Murakawa Y, Tamauchi M, Kaji H, Yamaguchi T, et al. Bone fragility in male
glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int.
2009;20(11):1889–1894.
Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H, et al. Analysis of bone metabolism during
early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic
diseases treated with high-dose glucocorticoid: early Diagnosis and Treatment of Osteoporosis in Japan
(EDITOR-J) study. J Bone Miner Metab. 2016;34(6):646–654.
Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, et al. Effect of intermittent cyclical etidronate
therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year
followup. J Rheumatol. 2003;30(12):2673–2679.
Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, et al. Longterm effect of intermittent cyclical
etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease:
7-year followup. J Rheumatol. 2008;35(11):142–146.
Tsujikawa T, Andoh A, Inatomi O, Bamba S, Nakahara T, Sasaki M, et al. Alendronate improves low bone
mineral density induced by steroid therapy in Crohn’s disease. Intern Med. 2009;48(12):933–937.
Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, et al. Risedronate, an effective treatment
for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUSCKD). Nephrol Dial Transplant. 2007;22(6):1601–1607.
Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, et al. Effect of risedronate on highdose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant.
2007;22(6):1593–1600.
Inoue K, Hamano T, Nango N, Matsui I, Tomida K, Mikami S, et al. Multidetector-row computed tomography
is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone
Miner Metab. 2014;32(3):271–280.
Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, et al. The effects of denosumab and
alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized,
controlled trial. PLoS One. 2018;13(3):e0193846.
Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and
treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research:
2014 update. J Bone Miner Metab. 2014;32(4):337–350.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese
equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J
Kidney Dis. 2009;53(6):982–992.
Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16.
BISPHOSPHONATE AND ACTIVE VITAMIN D ANALOG ON GIO IN PATIENTS WITH IGAN
24. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of
Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. Arthritis
Rheumatol. 2017;69(8):1521–1537.
25. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a metaanalysis. Osteoporos Int. 2002;13(10):777–787.
26. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk:
relationship to daily and cumulative doses. Rheumatology. 2000;39(12):1383–1389.
27. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ, et al. A meta-analysis of prior corticoid
use and fracture risk. J Bone Miner Res. 2004;19(6):893–899.
28. Ioannidis G, Pallan S, Papaioannou A, Mulgund M, Rios L, Ma J, et al. Glucocorticoid predict 10-year
fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre
Osteoporosis Study (CaMos). Arch Osteoporos. 2014;9:169.
29. Haugeberg G, Griffiths B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of
methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis.
2004;63(8):940–944.
30. Yoshida Y, Moriya A, Kitamura K, Inazu M, Okimoto N, Okazaki Y, et al. Responses of trabecular and
cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized
beagles with calcium restriction. J Bone Miner Res. 1998;13(6):1011–1022.
31. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al; Japanese Allied Committee on
Osteonecrosis of the Jaw. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the
Japanese allied committee on osteonecrosis of the jaw. J Bone Miner Metab. 2017;35(1):6–19.
E15
...
論文の公開元へ
